Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies

Haematologica

Volumn 97, Issue 2, 2012, Pages 213-218

  Adès, Lionel ^a   Le Bras, Fabien ^a   Sebert, Marie ^a   Kelaidi, Charikleia ^a   Lamy, Thierry ^a   Dreyfus, François ^a   Eclache, Virginie ^a   Delaunay, Jacques ^a   Bouscary, Didier ^a   Visanica, Sorin ^a   Turlure, Pascal ^a   Bresler, Agnès Guerci ^a   Cabrol, Marie Paule ^a   Banos, Anne ^a   Blanc, Michel ^a   Vey, Norbert ^a   Delmer, Alain ^a   Wattel, Eric ^a   Chevret, Sylvie ^a   Fenaux, Pierre ^a  

^a Groupe Francophone des Myelodysplasies   (France)

Author keywords

5q deletion; Acute myeloid leukemia; Lenalidomide; Myelodysplastic syndrome; Progression

Indexed keywords

LENALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CHROMOSOME 5Q; CHROMOSOME DELETION 5; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOGENETICS; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PROPENSITY SCORE; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; SURVIVAL RATE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84856487158     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.045914     Document Type: Article

References (17)

1. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89 (6):2079-88.
2. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385-95.
3. Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C, et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia. 2004;18(1): 113-9.
4. Giagounidis AA, Germing U, Wainscoat JS, Boultwood J, Aul C. The 5q- syndrome. Hematology. 2004;9(4):271-7.
5. Van den Berghe H, Michaux L. 5q-, twenty-five years later: a synopsis. Cancer Genet Cytogenet. 1997;94(1):1-7.
6. Kelaidi C, Park S, Brechignac S, Mannone L, Vey N, Dombret H, et al. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk Res. 2008;32(7):1049-53.
7. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355(14): 1456-65.
8. Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008; 111(2):574-82.
9. Tamburini J, Elie C, Park S, Beyne-Rauzy O, Gardembas M, Berthou C, et al. Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes. Leuk Res. 2009;33(4):547-50.
10. Bouscary D, Legros L, Tulliez M, Dubois S, Mahe B, Beyne-Rauzy O, et al. A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies. Br J Haematol. 2005;131(5):609-18.
11. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009; 28(25):3083-107.
12. Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med. 2008; 27(12):2037-49.
13. D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265-81.
14. Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Pfeilstocker M, et al. Survival, prognostic factors, and rates of leukemic transformation in a multicenter study of 303 untreated patients with MDS and del(5q). ASH Annual Meeting Abstracts 2009;114(22):945.
15. Giagounidis AA, Germing U, Strupp C, Hildebrandt B, Heinsch M, Aul C. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalido-mide in this patient subgroup. Ann Hematol. 2005;84(9):569-71.
16. Jadersten M, Saft L, Smith A, Kulasekararaj A, Pompllun S, Gohring G et al. TP53 mutations in low-risk MDS with del(5q) predict disease progression. J Clin Oncol. 2011; 29(15):1971-9.
17. Gohring G, Giagounidis A, Busche G, Kreipe HH, Zimmermann M, Hellstrom-Lindberg E, et al. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenet-ic remission after treatment with lenalido-mide have an increased risk for clonal evolution and AML progression. Ann Hematol. 2010;89(4):365-74.